Winners and Losers From the End of the Generic Drugs Wave
As the generics wave crests in the coming years, the dynamics of the pharmaceutical industry will change dramatically, say Morningstar's Matt Coffina and Michael Waterhouse.
Matt Coffina: For Morningstar StockInvestor, I'm Matt Coffina. I'm joined today by Michael Waterhouse, who is an equity analyst on our health-care team. We're going to talk about generic drug makers. Michael, thanks for joining me.
Michael Waterhouse: Thanks for having me, Matt.
Matthew Coffina has a position in the following securities mentioned above: NVS, ABT. Find out about Morningstar’s editorial policies.